Regeneron and Sanofi broke new ground in treating advanced basal cell carcinoma with their anti-PD-1 inhibitor, Libtayo.
If you are not happy with the results below please do another search
50 search results for:
A lower supply of a certain type of immune cell in older people that is critical to fighting foreign invaders may help explain their vulnerability to severe Covid-19, scientists say. An antiseptic nasal spray containing povidone-iodine may help curb transmission of the new coronavirus, preliminary research suggests.
AstraZeneca and Merck announced positive five-year follow-up data from the Phase III SOLO-1 trial which demonstrated a long-term progression-free survival benefit of Lynparza as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who were in complete or partial response to platinum-based chemotherapy.
A rheumatoid arthritis drug developed by Genentech proved to be effective in benefitting patients who have Covid-19-associated pneumonia, according to new late-stage clinical trial data.
Moderna Inc. expects to produce 20 million doses of the company’s experimental coronavirus vaccine by the end of 2020.
Europe’s healthcare regulator endorsed using dexamethasone to treat Covid-19 patients with breathing difficulties, paving the way for the steroid to become the region’s second approved treatment for the respiratory illness.
Russia approved R-Pharm’s Coronavir treatment for outpatients with mild to moderate Covid-19 infections and the antiviral drug could be rolled out to pharmacies in the country within a week, the company said.
Vaccinex Inc. will pair the company’s lead asset pepinemab with Merck & Co.’s vaunted checkpoint inhibitor Keytruda.
Silicon Valley medical equipment startup Visby Medical received Emergency Use Authorization by the U.S. Food and Drug Administration for a portable PCR Covid-19 test kit, the first company to do so, according to the FDA.
U.S. manufacturers are sharply increasing production of cheap, fast – but less accurate – Covid-19 tests, aiming for 100 million per month by year-end 2020 that will enable schools and workplaces to significantly expand testing.